Catalent and Redwood Bioscience Win Inaugural ‘Innovation In Partnering’ Award
Somerset, N.J. & Paris, France – October 8, 2014 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has won the inaugural ‘Innovation in Partnering’ Award at the annual CPhI Pharma Awards, for its work with Redwood Bioscience Inc. on the novel, site-specific SMARTag™ Antibody Drug Conjugate (ADC) technology.
The SMARTag platform enables the generation of homogenous bioconjugates, engineered to improve performance and ease of manufacturing. In earlier news, on October 3rd, Catalent announced that it had acquired the remaining stake in Redwood Bioscience, having previously held a minority share in the company.
The Catalent/Redwood partnership was one of three finalists selected by a panel of pharma industry experts, with the ultimate winner chosen by a public vote via the CPhI website. The award was presented at a ceremony on October 7th, at the world’s largest pharmaceutical event, CPhI Worldwide, which is currently taking place at Paris Nord Villepinte, France.
“We would like to thank the industry for their recognition of our work with Redwood for the development and marketing of the SMARTag platform, resulting in this prestigious award,” commented Barry Littlejohns, Catalent’s President of Advanced Delivery Technologies. “Prior to our acquisition of Redwood, we partnered closely with their team to demonstrate in vivo and in vitro proof of concept milestones for SMARTag, resulting in widespread industry interest.”
Redwood President, CSO and Founder, David Rabuka, who has now assumed the role of Head of R&D, Chemical Biology, with Catalent, added, “It is an honor to be acknowledged with this award by our industry peers. Combined with our recent acquisition by Catalent, this marks the start of the next exciting phase in the development of the SMARTag platform.”
Media Contacts:
Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com
Richard Kerns
+44 (0)161 728 5880
richard@nepr.eu
About Catalent
Catalent Pharma Solutions, is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com
More products. Better treatments. Reliably supplied.™
Forward-Looking Statements
This press release contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate”, “intend”, “estimate”, “plan”, “project”, “foresee”, “likely”, “may”, “will”, “would” or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent, Inc.’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: general industry conditions and competition; product or other liability risk inherent in the design, development, manufacture and marketing of our offerings; inability to enhance our existing or introduce new technology or services in a timely manner; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; and our substantial debt and debt service requirements that restrict our operating and financial flexibility and impose significant interest and financial costs. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in its Form 10-K release for the fiscal year ended June 30, 2014 filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent, Inc. does not undertake to update any forward-looking statements as a result of new information or future events or developments unless required by law.